top of page
CANVAS Fact Sheet
Ataxia:

CANVAS (Cerebellar ataxia, Neuropathy, and Vestibular Areflexia Syndrome)

RELATED GENES:

RFC1

LOCATION:

Chromosome 4 (region 4p14)

MUTATION TYPE:

Intronic AAGGG repeat expansion in the RFC1 gene

HERITAGE:

Autosomal Recessive

LAST UPDATE:

Sept 2, 2025 by Marcio Galvão

Content generated with the support of Generative AI, reviewed by the author.

1. ABOUT CANVAS

CANVAS is a rare, late-onset neurological disease, classically characterized by the triad of cerebellar ataxia, sensory neuropathy, and bilateral vestibular areflexia (from the English Cerebellar Ataxia with Neuropathy and bilateral Vestibular Areflexia Syndrome). It is an inherited genetic disorder with autosomal recessive transmission. For a long time, CANVAS was regarded as a form of idiopathic (i.e., of unknown cause) late-onset ataxia. In 2019, neurologist Andrea Cortese and colleagues identified that the disease is associated with mutations in the RFC1 (Replication Factor C subunit 1) gene, which encodes a protein essential for DNA replication and repair processes [1].

Dr. Cortese discovered that the most common cause of CANVAS is a biallelic expansion of the pentanucleotide repeat AAGGG in intron 2 of the RFC1 gene. It is therefore an intronic expansion (in a non-coding region of the gene). Although the exact mechanism causing the disease remains unknown (see Note), the consequence is progressive neuronal degeneration and, consequently, the clinical manifestation of the characteristic symptoms.

Structural neuroimaging signatures in patients with confirmed diagnosis reveal relatively symmetric cerebellar atrophy, brainstem volume reduction, and, in some studies, basal ganglia atrophy [3]. More recent findings include thinning of the cranial nerves V and VIII [4] and hypothalamic atrophy [5], the latter possibly correlating with autonomic symptoms (see 2. Symptoms).

Note! The pathogenesis of CANVAS is still under investigation. The most recent hypotheses include RNA-mediated toxic effects [6] derived from the AAGGG expansion, or direct AAGGG repeat–dependent toxicity [7], without reduced expression or loss of function of the RFC1 protein, which is unusual in autosomal recessive disorders [1].

Figure 1 – Simplified pathogenesis of CANVAS: Image generated with AI support.

Simplified diagram of the pathogenesis of CANVAS

2. TYPICAL SYMPTOMS

The typical symptoms of CANVAS are [2]:

  • Progressive cerebellar ataxia – unsteady gait, lack of motor coordination, abnormal eye movements (nystagmus, dysmetric saccades), dysarthria, and dysphagia (in more advanced stages).

  • Sensory neuronopathy (Note 1).

  • Bilateral vestibular areflexia – absent or reduced VOR, with visually enhanced VOR also impaired (Note 2).

  • Chronic dry cough (may appear many years before the onset of ataxia and neuropathy).

  • Autonomic dysfunction – cardiac problems, orthostatic hypotension, urinary dysfunction, sexual dysfunction, constipation, altered sweating (Note 3).

Other manifestations have also been described as part of the RFC1 spectrum, such as parkinsonism, pyramidal signs, neuropathic pain, and possible mild cognitive impairment. It should be noted that there is variability in the age of symptom onset even within the same family, and that in some cases the phenotype is incomplete — within the RFC1 symptom spectrum, some patients present only neuropathy or only vestibulopathy, usually with late onset (see 3. Onset).

Notes:

1 – When CANVAS syndrome was first clinically described in the 2000s, the “N” in the acronym was defined as neuropathy, since at that time it was believed to represent a classic peripheral sensory neuropathy. In that condition, the lesion occurs mainly in peripheral nerve fibers, and the symptoms follow a length-dependent pattern — starting in the feet or hands and progressing symmetrically. Subsequent neurophysiological and neuropathological studies, however, demonstrated that in CANVAS the primary lesion is not in the fibers, but rather in the cell bodies of the sensory neurons located in the dorsal root ganglia (DRG). It is therefore more accurately described as a sensory neuronopathy (or ganglionopathy), characterized by non–length-dependent symptoms — which may be asymmetric, multifocal, and often associated with proprioceptive loss leading to sensory ataxia. Thus, it is now recognized that the more appropriate term in the context of CANVAS is sensory neuronopathy, even though in the original acronym "CANVAS" the “N” continues to be read as “neuropathy” for historical reasons.

2 – The “normal” VOR corresponds to the basic vestibulo-ocular reflex, which depends on the integrity of the peripheral vestibular system (labyrinth and vestibular nerve). In patients with CANVAS, due to bilateral vestibular areflexia, this reflex is usually absent or severely reduced. In cases of isolated vestibular lesions, the cerebellum can use visual cues to partially compensate for vestibular failure, generating the so-called visually enhanced VOR. However, in CANVAS the cerebellum is also affected (cerebellar ataxia), so even the visually enhanced VOR is impaired.

3 – In CANVAS/RFC1, autonomic dysfunction is common and may involve several domains [2, 8, 9, 10]:

  • Cardiovascular autonomic: mainly orthostatic hypotension and orthostatic intolerance (this is not “structural” heart disease).

  • Urinary: incontinence/retention, neurogenic bladder.

  • Sexual: erectile dysfunction reported in cohorts.

  • Gastrointestinal: constipation (and other GI symptoms).

  • Sudomotor: reduced/altered sweating; there are reports of denervation of sweat glands.

 

Figure 2 – CANVAS diagram (adapted from [1]). The diagram illustrates the overlap between cerebellar ataxia, sensory neuronopathy, and bilateral vestibulopathy, whose intersection defines CANVAS syndrome.

Diagram with CANVAS syndrome at the intersection of cerebellar ataxia, neuropathy, and vestibular areflexia.

3. ONSET

CANVAS is a late-onset disease. Symptoms of CANVAS usually manifest in adulthood after the age of 35, with 52 years being the average age at onset of neurological manifestations.

Notes:

  • Chronic dry cough is often the first symptom of CANVAS to appear, and may precede neurological manifestations by as much as 20 to 30 years [1].

  • Symptomatic cases in adolescents have not yet been reported in the literature.

  • The progression is slow — the disease evolves over decades. About half of patients require a cane after 10 years of symptoms, and some eventually progress to wheelchair use thereafter.

  • Life expectancy is generally preserved.

4. ANTICIPATION

There is no robust evidence of genetic anticipation in CANVAS/RFC1 (children presenting with earlier and more severe symptoms than their parents). Moreover, because it follows an autosomal recessive inheritance pattern, the disease may appear to 'skip generations'.

5. INHERITANCE

CANVAS is inherited in an autosomal recessive manner. This means that individuals of both sexes have the same probability of inheriting the mutated gene. A person will only develop symptoms of the disease if they inherit two mutant copies (alleles) of the RFC1 gene — one from the biological father and one from the mother. Those who inherit only one mutant copy will be asymptomatic carriers. In these cases, the 'normal' copy of the gene is sufficient to maintain function, preventing the appearance of symptoms. In individuals who inherit two pathogenic copies of the RFC1 gene, however, the disease manifests, provided that the expansion falls within the range considered pathogenic (as explained below).

 

Ranges of AAGGG expansion for CANVAS diagnostic confirmation

Different types of pentanucleotide repeats may occur in intron 2 of the RFC1 gene (AAAAG, AAAGG, AAGGG, ACAGG, etc.), but so far, the most clearly pathogenic form is the expanded AAGGG [2]:

  • Normal range (not disease-causing):

    • AAAAG repeats: usually between 11 and ~200 repeats (stable, not disease-causing).

    • AAAGG repeats: may range from 40 up to >1000 repeats, also non-pathogenic.

  • Pathogenic range:

    • Expanded AAGGG: considered pathogenic with 400 or more repeats.

It should be emphasized that the mutation must be biallelic to cause the disease — that is, the individual must inherit one RFC1 allele in the pathogenic range from the father and another from the mother in order to develop CANVAS symptoms.

 

Note: Other pentanucleotide repeat combinations have been reported in certain populations and may be pathogenic when present in the biallelic state, such as ACAGG (Japan) and AAAGG/AAGGG (New Zealand Māori).

 

Probability of children inheriting the disease

Statistically, if both parents are carriers:

  • The probability that each child will develop the disease (= inherit one mutant allele from the mother and one from the father) is 25%.

  • The probability that each child will not develop the disease but will also be a carrier (= inherit only one mutant allele from either parent) is 50%.

  • The probability that each child will inherit no mutant allele (neither from the father nor the mother) — and thus will neither develop the disease nor be an asymptomatic carrier — is 25%.

 

The diagnosis of CANVAS requires specialized molecular genetic testing

A definitive diagnosis of CANVAS requires specialized molecular genetic testing. Since the causative mutation is a repeat expansion located in an intronic (non-coding) region of the RFC1 gene, it is not detected by conventional techniques such as NGS panels or clinical exome sequencing, which analyze only the exons (coding regions). To confirm the presence of the pathogenic expansion, specific methods are used, such as:

  • Repeat-primed PCR (RP-PCR), in combination with flanking PCR, which enables identification of the repetitive pentanucleotide (AAGGG);

  • Southern blot or long-read sequencing technologies (such as PacBio or Oxford Nanopore), which allow more accurate measurement of the expansion size.

Thus, exome sequencing alone is not sufficient to confirm the diagnosis of CANVAS, and these complementary approaches are required to detect and assess the size of the intronic expansion in RFC1.

 

Genetic counseling

Given the autosomal recessive inheritance of CANVAS, once a pathogenic variant in the RFC1 gene has been identified in a family member, genetic counseling is strongly recommended. It should be offered to adults who wish to have children as well as to first-degree relatives of affected individuals, in order to:

  • Assess the likelihood of being asymptomatic carriers;

  • Clarify the risks of transmission to offspring (25% chance of an affected child when both parents are carriers);

  • Discuss reproductive planning strategies and available testing options.

 

Note: "Autosomal" means the gene is located on any chromosome except the X and Y sex chromosomes. Genes, like chromosomes, typically exist in pairs (we have a pair of each gene; one copy of the gene is inherited from the mother, the other from the father). Thus, men and women are equally likely to inherit a mutated gene that can cause hereditary ataxia. "Recessive" means that two mutated copies (alleles) of the gene must be inherited (one from the biological father, the other from the mother) for a person to develop the disease.

Figure 3 - Source: MedlinePlus, US National Library of Medicine .

Diagram of autosomal recessive transmission

6. PREVALENCE

The exact population prevalence of CANVAS remains uncertain and varies across populations. Source [2] estimates that the frequency of heterozygous carriers of the AAGGG expansion in populations of European ancestry ranges between 0.7% and 4%, with a similar value (~2.24%) in Han Chinese. In this context, the estimated prevalence of individuals with biallelic expansions associated with CANVAS ranges from 1 in 20,000 (0.005%) to 1 in 625 (0.16%).

It is important to note that the prevalence estimate of “1 in 20,000” (equivalent to “5 cases per 100,000”) derives from theoretical calculations based on heterozygous carrier frequency and population genetics, rather than from clinical epidemiological studies, and appears to be an overestimate — the actual clinical prevalence of the syndrome may be lower than suggested by the theoretical calculation.

7. ADDITIONAL INFORMATION

CANVAS is a multisystem disease with a wide variety of symptoms. Differential diagnosis is important to distinguish CANVAS from other multisystem ataxias such as spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy–cerebellar type (MSA-C). For further information, see [2].

Symptoms:

  • The presence of the triad cerebellar ataxia + sensory neuronopathy (non–length-dependent) + bilateral vestibular areflexia favors the diagnosis of CANVAS.

  • Chronic dry cough (which often manifests long before neurological symptoms) favors CANVAS.

  • Neuropathy in SCA3 is usually axonal and length-dependent (sensorimotor). In contrast, CANVAS presents with sensory neuronopathy, often asymmetric and non–length-dependent.

Course:

  • CANVAS usually progresses slowly (vestibular and sensorimotor rehabilitation is beneficial), whereas MSA-C is rapidly progressive.

Family history:

  • CANVAS is autosomal recessive (symptoms may appear to “skip generations”), while in SCA3 (autosomal dominant), a positive family history is more common.

Neuroimaging:

  • Thinning of cranial nerves V and VIII helps differentiate CANVAS from SCAs and MSA-C.

Genetics:

  • MSA-C is sporadic, with no defining causal test.

  • SCA3 is genetic, caused by a CAG repeat expansion in the ATXN3 gene.

  • CANVAS is genetic, caused by an AAGGG repeat expansion in the RFC1 gene, confirmable by molecular genetic testing (RP-PCR/long-read).

8. THERAPIES AND DRUGS IN TESTS

There is currently no approved therapy to cure or modify the course of RFC1/CANVAS. Management is supportive, aimed at treating symptoms.

  • Bilateral vestibulopathy: Vestibular implants are in clinical trials in the US and Europe. In BVH (bilateral vestibular hypofunction), studies have shown improvement of the VOR and benefits in symptoms and quality of life. However, the method remains investigational, carries risks (including ipsilateral hearing loss), and no specific evidence exists for CANVAS at this time, although it may have potential future applicability [11].

  • Chronic cough: P2X3 antagonists (e.g., Gefapixant), already approved in Europe, may benefit patients with CANVAS (off-label use).

Note! For additional information on ongoing research and treatments for CANVAS, see Research and Treatment Development for CANVAS, NAF webinar with Dr. Andrea Cortese, February 19, 2024 [14].

9. TREATMENTS

Palliative and rehabilitative treatments:

  • Physical therapy: focus on balance, fall prevention, and proprioceptive training.

  • Vestibular rehabilitation: exercises to reduce symptoms of oscillopsia.

  • Speech therapy: support for dysarthria and dysphagia.

  • Management of painful neuropathy: use of standardized medications for neuropathic pain.

  • Management of dysautonomia: non-pharmacological strategies and specific medications according to the manifestation.

  • Chronic cough: multidisciplinary follow-up; consider modern therapies (P2X3) where available.

See information about medications for ataxia symptoms.

See information about treatments and care for patients.

See information about those with a recent diagnosis.

See information about Support Groups for patients and caregivers.

10. REFERENCES

The references below include academic sources and specialized organizations that supported the information in this technical sheet. For more information, see the ataxia.info References list .

Ref #1

Source:

Andrea Cortese et al

PubMed Central ® PMCID: PMC6709527.

Language:

English

Date:

2019

Ref #2

Source:

Andrea Cortese et al
Copyright © GeneReviews

Language:

English

Date:

November 25, 2020

Ref #3

Source:

Paula Camila A A P Matos et al

PubMed® PMID: 34241918.

Language:

English

Date:

Nov 2021

Ref #4

Source:

Camila C Lobo et al
PubMed® PMID: 38291837.

Language:

English

Date:

Jan 11, 2o24

Ref #5

Source:

Verena Miranda Souza et al
PubMed® PMID: 40526300.

Language:

English

Date:

Jun 17, 2025

Ref #6

Source:

Mohammad Hossein Abdi et al
PubMed Central ® PMCID: PMC10563062.

Language:

English

Date:

Sept 1, 2023

Ref #7

Source:

Connor J Maltby et al

PubMed Central ® PMCID: PMC10760133.

Language:

English

Date:

Dec 14, 2023

Ref #8

Source:

Teddy Y Wu et at

PubMed® PMID: 25070514

Language:

English

Date:

Oct 2014

Ref #9

Source:

Sullivan, Roisin et at
Current Opinion in Neurology. Published by Wolters Kluwer Health, Inc.

Language:

English

Date:

2021

Ref #10

Source:

Gabriel da Silva Schmitt et al
ScienceDirect. Copyright © 2025 Elsevier B.V

Language:

English

Date:

Oct 2022

Ref #11

Source:

Johns Hopkins University (Responsible Party)
ClinialTrials.gov

Language:

English

Date:

2025-07-14

Ref #12

Source:

Page with various resources for CANVAS patients and their caregivers
NAF (National Ataxia Foundation)

Language:

English, with translation available into other languages.

Date:

2025

Ref #13

Source:

Webinar apresentado pelo Dr. David Szmulewicz.
Canal da NAF no YouTube

Language:

Inglês

Date:

Feb 9, 2024

Ref #14

Source:

Webinar apresentado pelo Dr. Andrea Cortese
Canal da NAF no YouTube

Language:

Inglês

Date:

Feb 19, 2024

Ref #15

Source:

OMIM ® - An Online Catalog of Human Genes and Genetic Disorders.
Copyright © Johns Hopkins University.

Language:

Inglês

Date:

Edit History: carol : 01/15/2025

Content translated with AI support. Please read the Disclaimer .

bottom of page